A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice
R Jahagirdar, H Zhang, S Azhar, J Tobin, S Attwell… - Atherosclerosis, 2014 - Elsevier
Despite the benefit of statins in reducing cardiovascular risk, a sizable proportion of patients
still remain at risk. Since HDL reduces CVD risk through a process that involves formation of
pre-beta particles that facilitates the removal of cholesterol from the lipid-laden
macrophages in the arteries, inducing pre-beta particles, may reduce the risk of CVD. A
novel BET bromodomain antagonist, RVX-208, was reported to raise apoA-I and increase
preβ-HDL particles in non-human primates and humans. In the present study, we …
still remain at risk. Since HDL reduces CVD risk through a process that involves formation of
pre-beta particles that facilitates the removal of cholesterol from the lipid-laden
macrophages in the arteries, inducing pre-beta particles, may reduce the risk of CVD. A
novel BET bromodomain antagonist, RVX-208, was reported to raise apoA-I and increase
preβ-HDL particles in non-human primates and humans. In the present study, we …